United Therapeutics Q3 2024 GAAP EPS $6.39 Misses $6.43 Estimate, Sales $748.90M Beat $722.91M Estimate
Portfolio Pulse from Benzinga Newsdesk
United Therapeutics reported Q3 2024 earnings per share of $6.39, missing the consensus estimate of $6.43, but showed an 18.77% increase from last year. Sales were $748.90M, beating the estimate of $722.91M and showing a 22.89% increase from last year.
October 30, 2024 | 10:31 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
United Therapeutics' Q3 2024 earnings per share of $6.39 missed the consensus estimate of $6.43, but sales of $748.90M exceeded expectations. The earnings miss is minor, while the sales beat and significant year-over-year growth are positive indicators.
The slight miss in EPS is overshadowed by the strong sales performance, which exceeded expectations and showed significant growth compared to the previous year. This positive sales trend is likely to have a favorable impact on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100